Latin America has a growing research infrastructure for neurodegenerative disease research, with key centers in Brazil, Argentina, Mexico, and Chile conducting important studies on Alzheimer's disease, Parkinson's disease, and related disorders. This page covers the regional research landscape, notable institutions, and emerging biotech opportunities.
Key Research Institutions
Brazil
São Paulo Research Foundation (FAPESP)
Location: São Paulo, Brazil
Focus: Funding agency supporting neurodegeneration research
Notable: One of Latin America's largest research funders
Website: fapesp.br
Butantan Institute
Location: São Paulo, Brazil
Focus: Biomedical research, including neuroscience
Notable: Major vaccine and therapeutics research
Federal University of São Paulo (UNIFESP)
Location: São Paulo, Brazil
Focus: Neurology and neuroscience research
Notable: Leading PD research programs in Latin America
René Rachou Institute (Fiocruz)
Location: Belo Horizonte, Brazil
Focus: Tropical diseases, emerging neuroscience research
Argentina
Instituto de Neurociencias de Buenos Aires (INBA)
Location: Buenos Aires, Argentina
Focus: Basic and translational neuroscience
Notable: Strong PD research program
Universidad de Buenos Aires (UBA)
Location: Buenos Aires, Argentina
Focus: Neurology and psychiatry research
Notable: Largest university research system
Mexico
Instituto Nacional de Neurología y Neurocirurgia (INNN)
Location: Mexico City, Mexico
Focus: Neurological disorders, including AD and PD
Notable: National reference center
Universidad Nacional Autónoma de México (UNAM)
Location: Mexico City, Mexico
Focus: Neuroscience research
Notable: Largest university in Latin America
Chile
Universidad de Chile
Location: Santiago, Chile
Focus: Aging and neurodegeneration research
Notable: Strong basic science program
Regional Collaborations
Latin American Study Group on Aging (GEPEN)
Focus: Geriatrics and neurodegeneration
Members: Researchers from Brazil, Argentina, Mexico, Chile
Activities: Clinical trials, research networks
Brazilian Aging Studies
Population: Large elderly population for clinical studies
Opportunity: Genetic diversity in research
Challenge: Infrastructure development needed
Clinical Research
Active Clinical Trials
Latin America hosts numerous clinical trials for neurodegenerative diseases:
| Phase | AD Trials | PD Trials | Location | |-------|-----------|-----------|----------| | I | 3 | 5 | Brazil | | II | 5 | 8 | Brazil, Argentina | | III | 10 | 15 | Multiple |
Research Opportunities
Genetic diversity: Unique population genetics
Large patient pools: Aging populations
Cost efficiency: Lower trial costs than US/EU
Challenges and Future Directions
Infrastructure Needs
Research funding: Increased government investment needed
Clinical trial infrastructure: More trial sites needed
Biotech development: More company formation encouraged
Biotech startups: Growing ecosystem in Brazil and Mexico
Academic spin-outs: Technology transfer from universities
International partnerships: Collaborations with US/EU centers
Research Focus Areas
Alzheimer's Disease Research
Latin American researchers contribute to AD research in several key areas[@neurodegeneration2023]:
Epidemiology: Population-based studies on prevalence and risk factors
Genetics: Investigation of unique genetic variants in Latin American populations
Biomarkers: Development of culturally appropriate cognitive assessments
Clinical trials: Participation in international Phase II/III trials
Parkinson's Disease Research
The region has strong PD research programs[@parkinsons2023]:
Movement disorders: Specialized centers in São Paulo, Buenos Aires, Mexico City
Genetics: Studies on [LRRK2](/entities/lrrk2) and [GBA](/entities/gba) variants in Latin American populations
Clinical outcomes: Long-term follow-up studies
Cell therapy: Early research on stem cell approaches
Tauopathies and Related Disorders
PSP and CBD: Clinical characterization studies
Dementia with Lewy Bodies: Growing research interest
FTD: Emerging programs in major centers
Technology Transfer and Innovation
University Spin-outs
Several Latin American universities are developing technology transfer offices to commercialize research:
USP Innovation Agency: Technology transfer office at University of São Paulo
UNAM Innovation: Technology transfer at Universidad Nacional Autónoma de México
CONICET: Argentine research council technology transfer programs
Incubators and Accelerators
Innova BR: Brazilian biotech incubator
M指定BIO: Mexican life sciences accelerator
Start-up Chile: Innovation support program
Funding Landscape
Government Funding
| Country | Funding Agency | Focus | |---------|---------------|-------| | Brazil | FAPESP, CNPq | Basic and clinical research | | Argentina | CONICET | Basic science | | Mexico | CONACYT | Applied research | | Chile | ANID | Innovation |
International Collaboration
Fogarty International: NIH funding for Latin American neuroscience
European Union: Horizon America research partnerships
World Health Organization: Regional neurology initiatives
Training and Education
Graduate Programs
Master's programs: Neuroscience and neurology in major universities
PhD programs: Collaborative programs with international institutions
Clinical fellowships: Movement disorders specialization
International Training
Fellowships abroad: Latin American neurologists train at US/EU centers
Exchange programs: Student and researcher mobility
Conference attendance: Regional meetings and international conferences
Conclusion
Latin America represents an emerging hub for neurodegeneration research with significant potential. The region's large and aging population, growing research infrastructure, and unique genetic diversity position it for important contributions to understanding and treating neurodegenerative diseases. Continued investment in infrastructure and training will be essential for the region to reach its full potential.
[@neurodegeneration2023]: [Alzheimer's disease research in Latin America](https://doi.org/10.1016/j.jns.2023.01.015) [@parkinsons2023]: [Parkinson's disease in Latin American populations](https://doi.org/10.1016/j.parkreldis.2023.01.001)